NYSEAMERICAN:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis $0.45 -0.02 (-4.29%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.45▼$0.4950-Day Range N/A52-Week Range$0.36▼$44.80Volume85,870 shsAverage Volume241,248 shsMarket Capitalization$1.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get NovaBay Pharmaceuticals alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More NBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBY Stock News HeadlinesAugust 20, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (B9P0.F)August 14, 2024 | seekingalpha.comNovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 13, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals Inc. Q2 Loss DropsAugust 13, 2024 | msn.comNovaBay Q2 2024 Earnings PreviewAugust 1, 2024 | uk.investing.comNovaBay reports surge in Avenova sales during Prime DayJuly 30, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports Record Amazon Prime Day SalesSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.July 29, 2024 | msn.comWhat's Going On With NovaBay Pharmaceuticals (NBY) Stock?July 29, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment OptionJuly 27, 2024 | msn.comDow Surges 550 Points; Headline PCE Price Index Falls To 2.5%July 26, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public OfferingJuly 26, 2024 | benzinga.comWhy NovaBay Pharmaceuticals (NBY) Stock Is Down 60%July 25, 2024 | money.usnews.comNovabay Pharmaceuticals IncMay 20, 2024 | msn.comNovaBay Pharmaceuticals Stock Is Up 50%: What's Going On?May 13, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals is about to announce earnings — here's what Wall Street expectsSee More Headlines Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone(510) 899-8800Fax510-474-1577Employees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.9465) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-79.70% Pretax Margin-79.70% Return on Equity-146.20% Return on Assets-69.63% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.25 Sales & Book Value Annual Sales$14.40 million Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book0.29Miscellaneous Outstanding Shares4,210,000Free Float4,160,000Market Cap$1.88 million OptionableNot Optionable Beta2.82 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Justin M. Hall Esq. (Age 46)President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director Comp: $364.15kMr. Tommy Law (Age 39)Controller, Interim CFO & Treasurer Comp: $177.7kKey CompetitorsCyclerion TherapeuticsNASDAQ:CYCNOrganovoNASDAQ:ONVOObsEvaNASDAQ:OBSVCan-Fite BioPharmaNYSE:CANFKinetaNASDAQ:KAView All Competitors NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed this year? NovaBay Pharmaceuticals' stock was trading at $0.1802 at the start of the year. Since then, NBY shares have increased by 147.4% and is now trading at $0.4458. View the best growth stocks for 2024 here. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported ($1.37) EPS for the quarter. The biopharmaceutical company had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 79.70% and a negative trailing twelve-month return on equity of 146.20%. When did NovaBay Pharmaceuticals' stock split? NovaBay Pharmaceuticals's stock reverse split on the morning of Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO) and Matinas BioPharma (MTNB). This page (NYSEAMERICAN:NBY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovaBay Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
